Evidence map›Paper›PMID 26884153›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

Tailoring nanoparticle designs to target cancer based on tumor pathophysiology.

Edward A Sykes, Qin Dai, Christopher D Sarsons, Juan Chen, Jonathan V Rocheleau, David M Hwang, Gang Zheng, David T Cramb, Kristina D Rinker, Warren C W Chan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Clinical validation of a nanodiamond-embedded thermoplastic biomaterial.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Trial
  3. Article
  4. Article
  5. Intraorgan and targeted nanodelivery in organ transplantation of nonhuman primates.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. How Key in vivo Models Can Advance Anticancer Nanotherapeutics.International journal of nanomedicine · 2026
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Systemically targeting monocytic myeloid-derived suppressor cells using dendrimers and their cell-level biodistribution kinetics.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Edward A SykesInstitute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada M5S 3G9;
Qin DaiInstitute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada M5S 3G9;
Christopher D SarsonsBiomedical Engineering, University of Calgary, Calgary, AB, Canada T2N 1N4;
Juan ChenDepartment of Medical Biophysics, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada M5G 1L7;
Jonathan V RocheleauInstitute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada M5S 3G9; Toronto General Research Institute, University Health Network, Toronto, ON, Canada M5G 2M9;
David M HwangDepartment of Pathology, University Health Network, Toronto, ON, Canada M5G 2C4;
Gang ZhengDepartment of Medical Biophysics, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada M5G 1L7;
David T CrambDepartment of Chemistry, University of Calgary, Calgary, AB, Canada T2N 1N4;
Kristina D RinkerBiomedical Engineering, University of Calgary, Calgary, AB, Canada T2N 1N4;
Warren C W ChanInstitute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada M5S 3G9; Donnelly Center for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada M5S 3E1; Department of Chemistry, University of Toronto, ON, Canada M5S 3H6; Department of Chemical Engineering, University of Toronto, ON, Canada M5S 3E5; Department of Materials Science and Engineering, University of Toronto, ON, Canada M5S 3E4 warren.chan@utoronto.ca.

Funding

Canadian Institutes of Health Research COP126588Canadian Institutes of Health Research MOP130143
6 · The paper itself

Abstract

Nanoparticles can provide significant improvements in the diagnosis and treatment of cancer. How nanoparticle size, shape, and surface chemistry can affect their accumulation, retention, and penetration in tumors remains heavily investigated, because such findings provide guiding principles for engineering optimal nanosystems for tumor targeting. Currently, the experimental focus has been on particle design and not the biological system. Here, we varied tumor volume to determine whether cancer pathophysiology can influence tumor accumulation and penetration of different sized nanoparticles. Monte Carlo simulations were also used to model the process of nanoparticle accumulation. We discovered that changes in pathophysiology associated with tumor volume can selectively change tumor uptake of nanoparticles of varying size. We further determine that nanoparticle retention within tumors depends on the frequency of interaction of particles with the perivascular extracellular matrix for smaller nanoparticles, whereas transport of larger nanomaterials is dominated by Brownian motion. These results reveal that nanoparticles can potentially be personalized according to a patient's disease state to achieve optimal diagnostic and therapeutic outcomes.

Indexed as

Metal NanoparticlesAnimalsBreast NeoplasmsCell Line, TumorFemaleGoldHeterograftsHumansMaleMiceMice, NudeMonte Carlo MethodProstatic NeoplasmsGoldcancernano–bio interactionsnanoparticlestargetingtumor

Identifiers

PMID26884153
PMCPMC4780626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.